Drug Profile
Research programme: prostate cancer therapeutics - Sensei Biotherapeutics
Alternative Names: PAN-127Latest Information Update: 17 May 2018
Price :
$50
*
At a glance
- Originator Panacea Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 16 May 2018 Panacea Pharmaceuticals is now called Sensei Biotherapeutics
- 31 May 2010 Preclinical trials in Prostate cancer in USA (unspecified route)